LU88122A1 - Anticorps purifies specifiquement developpes contre le cdw52 - Google Patents

Anticorps purifies specifiquement developpes contre le cdw52 Download PDF

Info

Publication number
LU88122A1
LU88122A1 LU88122A LU88122A LU88122A1 LU 88122 A1 LU88122 A1 LU 88122A1 LU 88122 A LU88122 A LU 88122A LU 88122 A LU88122 A LU 88122A LU 88122 A1 LU88122 A1 LU 88122A1
Authority
LU
Luxembourg
Prior art keywords
antibody
column
cdw52
prepn
purified
Prior art date
Application number
LU88122A
Other languages
English (en)
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10683866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU88122(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of LU88122A1 publication Critical patent/LU88122A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LU88122A 1990-10-17 1992-05-27 Anticorps purifies specifiquement developpes contre le cdw52 LU88122A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909022547A GB9022547D0 (en) 1990-10-17 1990-10-17 Purified immunoglobulin
PCT/GB1991/001816 WO1992007084A1 (fr) 1990-10-17 1991-10-17 Anticorps purifies specifiquement developpes contre de le cdw52

Publications (1)

Publication Number Publication Date
LU88122A1 true LU88122A1 (fr) 1993-03-15

Family

ID=10683866

Family Applications (1)

Application Number Title Priority Date Filing Date
LU88122A LU88122A1 (fr) 1990-10-17 1992-05-27 Anticorps purifies specifiquement developpes contre le cdw52

Country Status (29)

Country Link
US (1) US5644036A (fr)
EP (1) EP0504363B2 (fr)
JP (1) JP2638680B2 (fr)
KR (2) KR960015399B1 (fr)
AT (2) ATA900791A (fr)
AU (3) AU658926B2 (fr)
BE (1) BE1004226A5 (fr)
BR (1) BR1100358A (fr)
CA (1) CA2069481C (fr)
CH (2) CH681305A5 (fr)
DE (1) DE69128774T3 (fr)
DK (1) DK0504363T4 (fr)
ES (2) ES2081742B1 (fr)
FI (2) FI110003B (fr)
FR (2) FR2668164A1 (fr)
GB (2) GB9022547D0 (fr)
GR (3) GR910100425A (fr)
HU (1) HUT64601A (fr)
IE (1) IE913560A1 (fr)
IL (3) IL102726A (fr)
IT (1) IT1250064B (fr)
LU (1) LU88122A1 (fr)
MX (1) MX9203794A (fr)
MY (2) MY119030A (fr)
NZ (2) NZ240247A (fr)
PT (2) PT99248B (fr)
TW (1) TW283710B (fr)
WO (1) WO1992007084A1 (fr)
ZA (2) ZA926191B (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
CA2120911A1 (fr) * 1991-10-15 1993-04-29 Geoffrey Hale Medicaments
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
GB9300501D0 (en) * 1993-01-09 1993-03-03 Wellcome Found Purification of immunoglobulin
EP0841942B2 (fr) † 1995-08-01 2007-12-12 Sanofi Pasteur Procede de production industrielle d'un vaccin contre l'encephalite japonaise et vaccin obtenu
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
BRPI9715219B8 (pt) 1996-02-09 2015-07-07 Abbvie Biotechnology Ltd Vetor recombinante de expressão, e célula hospedeira procariótica.
GB9603256D0 (en) * 1996-02-16 1996-04-17 Wellcome Found Antibodies
US20030023043A1 (en) * 2000-03-02 2003-01-30 Kazuhisa Uchida Method of separating and purifying protein
WO2002072615A1 (fr) * 2001-03-09 2002-09-19 Chugai Seiyaku Kabushiki Kaisha Methode de purification de proteines
ATE421536T1 (de) * 2001-06-05 2009-02-15 Genetics Inst Llc Verfahren zur reinigung stark anionischer proteine
GB0220894D0 (en) * 2002-09-09 2002-10-16 Millipore Uk Ltd Method of separation
JP5525118B2 (ja) 2002-09-11 2014-06-18 中外製薬株式会社 タンパク質精製方法
AU2003274011B2 (en) 2002-10-15 2010-03-04 Intercell Ag Nucleic acids coding for adhesion factor of group B streptococcus, adhesion factors of group B streptococcus and further uses thereof
GB0304576D0 (en) * 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
CA2548947A1 (fr) * 2003-12-22 2005-07-14 Genzyme Corporation Traitement anticorps anti-cd52 pour diabetes
DK1869065T3 (da) 2005-03-11 2020-06-08 Wyeth Llc Fremgangsmåde til kromatografi med svag opdeling
PL2275443T3 (pl) 2008-04-11 2016-05-31 Chugai Pharmaceutical Co Ltd Cząsteczka wiążąca antygen zdolna do wiązania dwóch lub więcej cząsteczek antygenu w sposób powtarzalny
MX342907B (es) 2009-05-13 2016-10-17 Genzyme Corp * El uso de un anticuerpo anti-cd52 monoclonal para el tratamiento de lupus.
CN102459628A (zh) 2009-05-13 2012-05-16 基酶有限公司 抗人cd52 免疫球蛋白
EP2519536A4 (fr) * 2009-12-29 2013-06-05 Reddys Lab Ltd Dr Purification des protéines par échange d'ions
EP2583973B1 (fr) 2010-06-21 2018-03-21 Kyowa Hakko Kirin Co., Ltd. Procédé de purification d'une protéine utilisant un acide aminé
RU2467783C2 (ru) * 2010-07-30 2012-11-27 Закрытое акционерное общество "БиоХимМак СТ" Способ хроматографического выделения иммуноглобулина
MX365235B (es) 2010-11-30 2019-05-28 Chugai Pharmaceutical Co Ltd Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno.
EP2702077A2 (fr) 2011-04-27 2014-03-05 AbbVie Inc. Procédé de contrôle du profil de galactosylation de protéines exprimées de manière recombinante
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (fr) 2012-04-20 2013-10-24 Abbvie Inc. Procédés de modulation de la distribution de variant de lysine c-terminal
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9650411B2 (en) 2012-08-07 2017-05-16 Kyowa Hakko Kirin Co., Ltd. Method of purifying protein
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9206390B2 (en) 2012-09-02 2015-12-08 Abbvie, Inc. Methods to control protein heterogeneity
CA2905010A1 (fr) 2013-03-12 2014-09-18 Abbvie Inc. Anticorps humains qui se lient au tnf-alpha et leurs procedes de preparation
WO2014151878A2 (fr) 2013-03-14 2014-09-25 Abbvie Inc. Procédés pour la modulation des profils de glycosylation de protéines de traitements à base de protéines recombinantes au moyen de monosaccharides et d'oligosaccharides
WO2014159579A1 (fr) 2013-03-14 2014-10-02 Abbvie Inc. Anticorps anti-tnfα ayant mutés et leurs procédés d'utilisation
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
EP3052640A2 (fr) 2013-10-04 2016-08-10 AbbVie Inc. Utilisation d'ions métaux pour la modulation des profils de glycosylation de protéines recombinantes
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (fr) 2013-11-15 2015-05-21 Abbvie, Inc. Compositions de protéines de liaison génétiquement glycomodifiées
JP6722455B2 (ja) 2013-12-27 2020-07-15 中外製薬株式会社 等電点の低い抗体の精製方法
KR102650420B1 (ko) 2014-12-19 2024-03-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
WO2017022651A1 (fr) 2015-07-31 2017-02-09 中外製薬株式会社 Procédé de purification d'une composition comprenant des anticorps avec un polymère anionique
US10688412B2 (en) 2016-07-25 2020-06-23 Cehpalon, Inc. Affinity chromatography wash buffer
EP3494991A4 (fr) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Composition pour la prophylaxie ou le traitement de maladies liées à il-8
US20220177518A1 (en) 2019-03-29 2022-06-09 Asahi Kasei Medical Co., Ltd. Method for purifying protein
CN113692420B (zh) 2019-04-08 2023-09-12 旭化成医疗株式会社 用于纯化含蛋白质的溶液的聚酰胺介质及其制造方法
SG11202110986YA (en) 2019-04-10 2021-11-29 Chugai Pharmaceutical Co Ltd Method for purifying fc region-modified antibody
WO2022260091A1 (fr) 2021-06-10 2022-12-15 三菱ケミカル株式会社 Adsorbant synthétique, procédé de purification d'anticorps et procédé de production d'anticorps

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118796A (en) * 1987-12-09 1992-06-02 Centocor, Incorporated Efficient large-scale purification of immunoglobulins and derivatives
AU618989B2 (en) * 1988-02-12 1992-01-16 British Technology Group Limited Improvements in or relating to antibodies

Also Published As

Publication number Publication date
MY136210A (en) 2008-08-29
AU649078B2 (en) 1994-05-12
HU9202000D0 (en) 1992-10-28
FI110002B (fi) 2002-11-15
IL99761A0 (en) 1992-08-18
FI922380A0 (fi) 1992-05-25
CH681305A5 (fr) 1993-02-26
AU716402B2 (en) 2000-02-24
HUT64601A (en) 1994-01-28
DE69128774D1 (de) 1998-02-26
AU4521897A (en) 1998-02-12
ZA926191B (en) 1993-04-16
ES2112865T5 (es) 2007-09-16
CH681455A5 (fr) 1993-03-31
AU2532192A (en) 1993-02-11
AU7024294A (en) 1995-01-05
ITRM910788A0 (it) 1991-10-16
CA2069481A1 (fr) 1992-04-18
US5644036A (en) 1997-07-01
GR920100471A (el) 1994-06-30
CA2069481C (fr) 2003-07-29
ES2081742A1 (es) 1996-03-01
EP0504363A1 (fr) 1992-09-23
GR3026588T3 (en) 1998-07-31
AU658926B2 (en) 1995-05-04
GB2253397A (en) 1992-09-09
DK0504363T3 (da) 1998-09-21
FI922380A (fi) 1992-05-25
GB9022547D0 (en) 1990-11-28
AU8729491A (en) 1992-05-20
DE69128774T3 (de) 2007-08-16
ITRM910788A1 (it) 1993-04-16
PT99248A (pt) 1993-06-30
MY119030A (en) 2005-03-31
FR2668164B1 (fr) 1995-04-14
IE913560A1 (en) 1992-04-22
BE1004226A5 (fr) 1992-10-13
KR920703108A (ko) 1992-12-17
EP0504363B1 (fr) 1998-01-21
JP2638680B2 (ja) 1997-08-06
PT100988B (pt) 1999-08-31
FI922824A0 (fi) 1992-06-17
NZ244114A (en) 1995-06-27
FI922824A (fi) 1992-06-17
NZ240247A (en) 1994-03-25
JPH05504579A (ja) 1993-07-15
EP0504363B2 (fr) 2007-02-07
FI110003B (fi) 2002-11-15
ZA918259B (en) 1993-04-16
ES2081742B1 (es) 1996-10-01
FR2668164A1 (fr) 1992-04-24
ATA900791A (de) 1996-06-15
IL102726A0 (en) 1993-01-31
KR100193314B1 (ko) 1999-06-15
PT99248B (pt) 1999-04-30
GB9209529D0 (en) 1992-07-01
FR2677997A1 (fr) 1992-12-24
ATE162552T1 (de) 1998-02-15
WO1992007084A1 (fr) 1992-04-30
MX9203794A (es) 1992-07-01
IT1250064B (it) 1995-03-30
DK0504363T4 (da) 2007-05-29
IL102726A (en) 2002-08-14
PT100988A (pt) 1994-02-28
KR960015399B1 (ko) 1996-11-13
ES2112865T3 (es) 1998-04-16
GR910100425A (el) 1992-09-25
TW283710B (fr) 1996-08-21
BR1100358A (pt) 2000-03-28
DE69128774T2 (de) 1998-06-04

Similar Documents

Publication Publication Date Title
LU88122A1 (fr) Anticorps purifies specifiquement developpes contre le cdw52
MX9603637A (es) Purificacion de anticuerpo.
EP0185034A4 (fr)
ES8100502A1 (es) Un procedimiento para purificar proteinas con pesos moleculares superiores a 12.000,en particular interferon
AU7067287A (en) Method and apparatus for separating proteins
FR2487642B2 (fr) Procede de preparation de fractions proteiques par ultrafiltration et chromatographie d'exclusion et d'echange d'ions
Dimitrijevic et al. Purification and characterization of an estrogen-binding peroxidase from human fetuses
EP0310719A1 (fr) Methode de purification d'anticorps
Ninfali et al. Goat immunoglobulin purification on phosphocellulose and DEAE Affi-Gel blue
Coligan et al. Physical, chemical and immunological characterization of saline-extracted, concanavalin A-purified carcinoembryonic antigen
SE8902230D0 (sv) Interferon purification process
von Bahr-Lindström et al. Analytical and Preparative Applications of High-Performance Liquid Chromatography. Comparisons with Other Methods
FR2411202A1 (fr) Procede d'extraction et de purification de la globuline transporteur d'hormones thyroidiennes tbg